The influence of disease and comorbidity risk assessments on the survival of MDS and oligoblastic AML patients treated with 5-azacitidine: A retrospective analysis in ten centers of the "Rete Ematologica Lombarda"

Alfredo Molteni; Marta Riva; L. Borin; Massimo Bernardi; Anna Maria Pelizzari; Alessandra Freyrie; Matteo Giovanni Della Porta; Michele Nichelatti; Emanuele Ravano; Giulia Quaresmini; Jacopo Mariotti; Domenica Caramazza; Marta Ubezio; Simona Guarco; Federica Gigli; Rosa Greco; Roberto Cairoli; Enrica Morra

doi:10.1016/j.leukres.2016.01.006

The influence of disease and comorbidity risk assessments on the survival of MDS and oligoblastic AML patients treated with 5-azacitidine: A retrospective analysis in ten centers of the "Rete Ematologica Lombarda"

Alfredo Molteni, Marta Riva, L. Borin, Massimo Bernardi, Anna Maria Pelizzari, Alessandra Freyrie, Matteo Giovanni Della Porta, Michele Nichelatti, Emanuele Ravano, Giulia Quaresmini, Jacopo Mariotti, Domenica Caramazza, Marta Ubezio, Simona Guarco, Federica Gigli, Rosa Greco, Roberto Cairoli, Enrica Morra

Research output: Contribution to journal › Article

Abstract

5-Azacytidine is an effective therapy in high risk MDS and oligoblastic AML. This "real life" analysis was made on 185 patients treated with 5-azacytidine in 10 centers afferent to REL ("Rete Ematologica Lombarda"), a network in Lombardia region. The aim was to assess the influence of disease and comorbidity risk assessments on the survival. The results confirm the utility of 5-azacitidine in prolonging OS regardless of advanced age and the presence of comorbidities. They also encourage an early treatment since patients with IPSS-R High risk MDS have better outcome with respect to Very High risk ones. According to the IPSS cytogenetic risk, there was no difference in the outcome between Intermediate and High risk patients. Nevertheless, a poorer cytogenetic risk, according to the IPSS-R cytogenetic stratification, negatively influenced the outcome.

Original language	English
Pages (from-to)	21-27
Number of pages	7
Journal	Leukemia Research
Volume	42
DOIs	https://doi.org/10.1016/j.leukres.2016.01.006
Publication status	Published - Mar 1 2016

Fingerprint

Keywords

5-Azacytidine
High risk myelodysplastic syndromes
Oligoblastic acute myeloid leukemia
Prognostic indices

ASJC Scopus subject areas

Cancer Research
Hematology
Oncology

Cite this

Molteni, A., Riva, M., Borin, L., Bernardi, M., Pelizzari, A. M., Freyrie, A., Della Porta, M. G., Nichelatti, M., Ravano, E., Quaresmini, G., Mariotti, J., Caramazza, D., Ubezio, M., Guarco, S., Gigli, F., Greco, R., Cairoli, R., & Morra, E. (2016). The influence of disease and comorbidity risk assessments on the survival of MDS and oligoblastic AML patients treated with 5-azacitidine: A retrospective analysis in ten centers of the "Rete Ematologica Lombarda". Leukemia Research, 42, 21-27. https://doi.org/10.1016/j.leukres.2016.01.006

The influence of disease and comorbidity risk assessments on the survival of MDS and oligoblastic AML patients treated with 5-azacitidine : A retrospective analysis in ten centers of the "Rete Ematologica Lombarda". / Molteni, Alfredo; Riva, Marta; Borin, L.; Bernardi, Massimo; Pelizzari, Anna Maria; Freyrie, Alessandra ; Della Porta, Matteo Giovanni; Nichelatti, Michele; Ravano, Emanuele; Quaresmini, Giulia; Mariotti, Jacopo; Caramazza, Domenica; Ubezio, Marta; Guarco, Simona; Gigli, Federica; Greco, Rosa; Cairoli, Roberto; Morra, Enrica.

In: Leukemia Research, Vol. 42, 01.03.2016, p. 21-27.

Research output: Contribution to journal › Article

Molteni, A, Riva, M, Borin, L, Bernardi, M, Pelizzari, AM, Freyrie, A , Della Porta, MG, Nichelatti, M, Ravano, E, Quaresmini, G, Mariotti, J, Caramazza, D, Ubezio, M, Guarco, S, Gigli, F, Greco, R, Cairoli, R & Morra, E 2016, 'The influence of disease and comorbidity risk assessments on the survival of MDS and oligoblastic AML patients treated with 5-azacitidine: A retrospective analysis in ten centers of the "Rete Ematologica Lombarda"', Leukemia Research, vol. 42, pp. 21-27. https://doi.org/10.1016/j.leukres.2016.01.006

Molteni A, Riva M, Borin L, Bernardi M, Pelizzari AM, Freyrie A et al. The influence of disease and comorbidity risk assessments on the survival of MDS and oligoblastic AML patients treated with 5-azacitidine: A retrospective analysis in ten centers of the "Rete Ematologica Lombarda". Leukemia Research. 2016 Mar 1;42:21-27. https://doi.org/10.1016/j.leukres.2016.01.006

Molteni, Alfredo ; Riva, Marta ; Borin, L. ; Bernardi, Massimo ; Pelizzari, Anna Maria ; Freyrie, Alessandra ; Della Porta, Matteo Giovanni ; Nichelatti, Michele ; Ravano, Emanuele ; Quaresmini, Giulia ; Mariotti, Jacopo ; Caramazza, Domenica ; Ubezio, Marta ; Guarco, Simona ; Gigli, Federica ; Greco, Rosa ; Cairoli, Roberto ; Morra, Enrica. / The influence of disease and comorbidity risk assessments on the survival of MDS and oligoblastic AML patients treated with 5-azacitidine : A retrospective analysis in ten centers of the "Rete Ematologica Lombarda". In: Leukemia Research. 2016 ; Vol. 42. pp. 21-27.

@article{4b555f4c01544376a4ee31bcb12e7c19,

title = "The influence of disease and comorbidity risk assessments on the survival of MDS and oligoblastic AML patients treated with 5-azacitidine: A retrospective analysis in ten centers of the {"}Rete Ematologica Lombarda{"}",

abstract = "5-Azacytidine is an effective therapy in high risk MDS and oligoblastic AML. This {"}real life{"} analysis was made on 185 patients treated with 5-azacytidine in 10 centers afferent to REL ({"}Rete Ematologica Lombarda{"}), a network in Lombardia region. The aim was to assess the influence of disease and comorbidity risk assessments on the survival. The results confirm the utility of 5-azacitidine in prolonging OS regardless of advanced age and the presence of comorbidities. They also encourage an early treatment since patients with IPSS-R High risk MDS have better outcome with respect to Very High risk ones. According to the IPSS cytogenetic risk, there was no difference in the outcome between Intermediate and High risk patients. Nevertheless, a poorer cytogenetic risk, according to the IPSS-R cytogenetic stratification, negatively influenced the outcome.",

keywords = "5-Azacytidine, High risk myelodysplastic syndromes, Oligoblastic acute myeloid leukemia, Prognostic indices",

author = "Alfredo Molteni and Marta Riva and L. Borin and Massimo Bernardi and Pelizzari, {Anna Maria} and Alessandra Freyrie and {Della Porta}, {Matteo Giovanni} and Michele Nichelatti and Emanuele Ravano and Giulia Quaresmini and Jacopo Mariotti and Domenica Caramazza and Marta Ubezio and Simona Guarco and Federica Gigli and Rosa Greco and Roberto Cairoli and Enrica Morra",

year = "2016",

month = mar

day = "1",

doi = "10.1016/j.leukres.2016.01.006",

language = "English",

volume = "42",

pages = "21--27",

journal = "Leukemia Research",

issn = "0145-2126",

publisher = "Elsevier Ltd",

}

TY - JOUR

T1 - The influence of disease and comorbidity risk assessments on the survival of MDS and oligoblastic AML patients treated with 5-azacitidine

T2 - A retrospective analysis in ten centers of the "Rete Ematologica Lombarda"

AU - Molteni, Alfredo

AU - Riva, Marta

AU - Borin, L.

AU - Bernardi, Massimo

AU - Pelizzari, Anna Maria

AU - Freyrie, Alessandra

AU - Della Porta, Matteo Giovanni

AU - Nichelatti, Michele

AU - Ravano, Emanuele

AU - Quaresmini, Giulia

AU - Mariotti, Jacopo

AU - Caramazza, Domenica

AU - Ubezio, Marta

AU - Guarco, Simona

AU - Gigli, Federica

AU - Greco, Rosa

AU - Cairoli, Roberto

AU - Morra, Enrica

PY - 2016/3/1

Y1 - 2016/3/1

N2 - 5-Azacytidine is an effective therapy in high risk MDS and oligoblastic AML. This "real life" analysis was made on 185 patients treated with 5-azacytidine in 10 centers afferent to REL ("Rete Ematologica Lombarda"), a network in Lombardia region. The aim was to assess the influence of disease and comorbidity risk assessments on the survival. The results confirm the utility of 5-azacitidine in prolonging OS regardless of advanced age and the presence of comorbidities. They also encourage an early treatment since patients with IPSS-R High risk MDS have better outcome with respect to Very High risk ones. According to the IPSS cytogenetic risk, there was no difference in the outcome between Intermediate and High risk patients. Nevertheless, a poorer cytogenetic risk, according to the IPSS-R cytogenetic stratification, negatively influenced the outcome.

AB - 5-Azacytidine is an effective therapy in high risk MDS and oligoblastic AML. This "real life" analysis was made on 185 patients treated with 5-azacytidine in 10 centers afferent to REL ("Rete Ematologica Lombarda"), a network in Lombardia region. The aim was to assess the influence of disease and comorbidity risk assessments on the survival. The results confirm the utility of 5-azacitidine in prolonging OS regardless of advanced age and the presence of comorbidities. They also encourage an early treatment since patients with IPSS-R High risk MDS have better outcome with respect to Very High risk ones. According to the IPSS cytogenetic risk, there was no difference in the outcome between Intermediate and High risk patients. Nevertheless, a poorer cytogenetic risk, according to the IPSS-R cytogenetic stratification, negatively influenced the outcome.

KW - 5-Azacytidine

KW - High risk myelodysplastic syndromes

KW - Oligoblastic acute myeloid leukemia

KW - Prognostic indices

UR - http://www.scopus.com/inward/record.url?scp=84960845295&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84960845295&partnerID=8YFLogxK

U2 - 10.1016/j.leukres.2016.01.006

DO - 10.1016/j.leukres.2016.01.006

M3 - Article

VL - 42

SP - 21

EP - 27

JO - Leukemia Research

JF - Leukemia Research

SN - 0145-2126

ER -

Access to Document

10.1016/j.leukres.2016.01.006